More recently, a series of reports have demonstrated that the pro-inflammatory properties of angiotensin II are mediated by AT1R and that non-thiol ACEIs and AT1R blockade can have therapeutic benefits in the treatment of RA and other autoimmune diseases 6–30. Here, AGTR1 is linked to autoimmune disease.